Boryung Corporation

KSE 003850.KS

Boryung Corporation Operating Income for the year ending December 31, 2023: USD 52.43 M

Boryung Corporation Operating Income is USD 52.43 M for the year ending December 31, 2023, a 17.25% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Boryung Corporation Operating Income for the year ending December 31, 2022 was USD 44.72 M, a -23.09% change year over year.
Boryung Corporation Operating Income for the year ending December 31, 2021 was USD 58.14 M, a 58.38% change year over year.
Boryung Corporation Operating Income for the year ending December 31, 2020 was USD 36.71 M, a 9.01% change year over year.
Boryung Corporation Operating Income for the year ending December 31, 2019 was USD 33.67 M, a 50.93% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

KSE: 003850.KS

Boryung Corporation

CEO	Mr. Jay Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	136, Changgyeonggung-ro
Employees	1,533
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care Plastics

Description

Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.

Key trends

Past 5 years